TG Therapeutics, Inc. (TGTX)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about TG Therapeutics, Inc. (TGTX)
Go deeper and ask any question about TGTX
Company Performance
Current Price
as of Oct 04, 2024$22.23
P/E Ratio
37.04
Market Cap
$3.44B
Description
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Metrics
Overview
- HQMorrisville, NC
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerTGTX
- Price$22.23+0.18%
Trading Information
- Market Cap$3.44B
- Float89.12%
- Average Daily Volume (1m)4,605,043
- Average Daily Volume (3m)3,647,222
- EPS$0.67
Company
- Revenue$346.73M
- Rev Growth (1yr)357.05%
- Net Income$6.88M
- Gross Margin88.60%
- EBITDA Margin12.10%
- EBITDA$8.89M
- EV$2.73B
- EV/Revenue7.88
- P/E37.04
- P/S10.22
Documents
SEC Filings
Earnings Calls